ARMR Sciences to begin human clinical trials for fentanyl vaccine

Collin Gage of ARMR Sciences announced that human clinical trials for their fentanyl vaccine are set to begin next month or early next year. He revealed that the research was initially funded by the Department of War, recognizing fentanyl as a potential chemical threat and a national security crisis. Gage anticipates the vaccine could be available on the market within two to five years, pending regulatory approvals.